Visualizing the replication of respiratory syncytial virus in cells and in living mice

Nature Communications

Volumn 5, Issue , 2014, Pages

  Rameix Welti, Marie Anne ^a,b,c   Le Goffic, Ronan ^a   Hervé, Pierre Louis ^a   Sourimant, Julien ^a,b   Rémot, Aude ^a   Riffault, Sabine ^a   Yu, Qin ^d   Galloux, Marie ^a   Gault, Elyanne ^b,c   Eléouët, Jean François ^a  

^a INRA Institut National de la Recherche Agronomique   (France)

^b Laboratoire de Microbiologie   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIREFLY LUCIFERASE; RED FLUORESCENT PROTEIN; ANTIVIRUS AGENT; COMPLEMENTARY DNA; LUCIFERASE; PHOTOPROTEIN; RECOMBINANT PROTEIN; VIRUS ANTIBODY; VIRUS FUSION PROTEIN;

BIOLUMINESCENCE; DISEASE; GENOME; INOCULATION; PROTEIN; VACCINE; VIRUS;

ARTICLE; BIOLUMINESCENCE; CELL CULTURE; GENE EXPRESSION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFECTION RATE; NONHUMAN; REVERSE GENETICS; VIRUS GENOME; VIRUS RECOMBINANT; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; CHEMISTRY; DNA REPLICATION; FEMALE; FLUORESCENCE; FLUORESCENCE MICROSCOPY; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; LUMINESCENCE; METABOLISM; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PHYSIOLOGY;

HUMAN RESPIRATORY SYNCYTIAL VIRUS; MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BASE SEQUENCE; DNA REPLICATION; DNA, COMPLEMENTARY; FEMALE; FLUORESCENCE; GENETIC VECTORS; HUMANS; LUCIFERASES; LUMINESCENCE; LUMINESCENT PROTEINS; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS; VIRUS REPLICATION;

EID: 84923360039     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6104     Document Type: Article

References (37)

1. Tregoning, J. S. & Schwarze, J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin. Microbiol. Rev. 23, 74-98 (2010).
2. Renshaw, R. W., Zylich, N. C., Laverack, M. A., Glaser, A. L. & Dubovi, E. J. Pneumovirus in dogs with acute respiratory disease. Emerg. Infect. Dis. 16, 993-995 (2010).
3. Collins, P. L. & Crowe, J. E. In Fields Virology 5th edn (eds Knipe, D. M. & Howley, P. M.) 1601-1646 (Lippincott Williams & Wilkins, 2007).
4. Barik, S. Transcription of human respiratory syncytial virus genome RNA in vitro: requirement of cellular factor(s). J. Virol. 66, 6813-6818 (1992).
5. Dickens, L. E., Collins, P. L. &Wertz, G. W. Transcriptional mapping of human respiratory syncytial virus. J. Virol. 52, 364-369 (1984).
6. Collins, P. L. et al. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 50 proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl Acad. Sci. USA 92, 11563-11567 (1995).
7. Bem, R. A., Domachowske, J. B. & Rosenberg, H. F. Animal models of human respiratory syncytial virus disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 301, L148-L156 (2011).
8. Hallak, L. K., Collins, P. L., Knudson, W. & Peeples, M. E. Iduronic acidcontaining glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology 271, 264-275 (2000).
9. Cheng, X., Munoz, M. G., Zhou, H. & Jin, H. Expression of beta-galactosidase by recombinant respiratory syncytial viruses for microneutralization assay. J. Virol. Methods 105, 287-296 (2002).
10. Hotard, A. L. et al. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 434, 129-136 (2012).
11. Fuentes, S. et al. Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection. Vaccine 31, 3987-3994 (2013).
12. Burke, C. W. et al. Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy. PLoS Pathog. 7, e1002134 (2011).
13. Cook, S. H. & Griffin, D. E. Luciferase imaging of a neurotropic viral infection in intact animals. J. Virol. 77, 5333-5338 (2003).
14. Schoggins, J. W. et al. Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro. Proc. Natl Acad. Sci. USA 109, 14610-14615 (2012).
15. Luker, K. E., Hutchens, M., Schultz, T., Pekosz, A. & Luker, G. D. Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology 341, 284-300 (2005).
16. Luker, G. D. et al. Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J. Virol. 76, 12149-12161 (2002).
17. Hofherr, S. E., Shashkova, E. V., Weaver, E. A., Khare, R. & Barry, M. A. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol. Ther. 16, 1276-1282 (2008).
18. Raaben, M., Prins, H. J., Martens, A. C., Rottier, P. J. & De Haan, C. A. Non-invasive imaging of mouse hepatitis coronavirus infection reveals determinants of viral replication and spread in vivo. Cell. Microbiol. 11, 825-841 (2009).
19. Pan, W. et al. Visualizing influenza virus infection in living mice. Nat Commun. 4, 2369 (2013).
20. Heaton, N. S. et al. In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies. J. Virol. 87, 8272-8281 (2013).
21. Fix, J., Galloux, M., Blondot, M. L. & Eleouet, J. F. The insertion of fluorescent proteins in a variable region of respiratory syncytial virus L polymerase results in fluorescent and functional enzymes but with reduced activities. Open Virol. J. 5, 103-108 (2011).
22. Ruggli, N., Tratschin, J. D., Mittelholzer, C. & Hofmann, M. A. Nucleotide sequence of classical swine fever virus strain Alfort/187 and transcription of infectious RNA from stably cloned full-length cDNA. J. Virol. 70, 3478-3487 (1996).
23. Cianci, C. et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob. Agents Chemother. 48, 413-422 (2004).
24. Cianci, C. et al. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob. Agents Chemother. 48, 2448-2454 (2004).
25. Xiong, H. et al. Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor. Bioorg. Med. Chem. Lett. 23, 6789-6793 (2013).
26. Tiong-Yip, C. L. et al. Characterization of a respiratory syncytial virus L protein inhibitor. Antimicrob. Agents Chemother. 58, 3867-3873 (2014).
27. Buckley, S. M. et al. Luciferin detection after intranasal vector delivery is improved by intranasal rather than intraperitoneal luciferin administration. Hum. Gene Ther. 19, 1050-1056 (2008).
28. Empey, K. M., Peebles, Jr. R. S. & Kolls, J. K. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin. Infect. Dis. 50, 1258-1267 (2010).
29. Debing, Y., Jochmans, D. & Neyts, J. Intervention strategies for emerging viruses: use of antivirals. Curr. Opin. Virol. 3, 217-224 (2013).
30. van Remmerden, Y. et al. An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting. Virol. J. 9, 253 (2012).
31. Wan, X. Y. et al. Real-time light scattering tracking of gold nanoparticlesbioconjugated respiratory syncytial virus infecting HEp-2 cells. Sci. Rep. 4, 4529 (2014).
32. Prince, G. A., Horswood, R. L., Berndt, J., Suffin, S. C. & Chanock, R. M. Respiratory syncytial virus infection in inbred mice. Infect. Immun. 26, 764-766 (1979).
33. Lukacs, N. W. et al. Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus. Am. J. Pathol. 169, 977-986 (2006).
34. Moore, M. L. et al. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J. Virol. 83, 4185-4194 (2009).
35. DeVincenzo, J. P. et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 182, 1305-1314 (2010).
36. Buchholz, U. J., Finke, S. & Conzelmann, K. K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73, 251-259 (1999).
37. Matrosovich, M., Matrosovich, T., Garten, W. & Klenk, H. D. New low-viscosity overlay medium for viral plaque assays. Virol. J. 3, 63 (2006).